Vertex Pharmaceuticals Inc. Third Quarter Earnings Sneak Peek

Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) will unveil its latest earnings on Thursday, October 27, 2011. Vertex Pharmaceuticals is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Vertex Pharmaceuticals, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 15 cents per share, a swing from net loss of 99 cents in the year earlier quarter. During the past three months, the average estimate has moved up from a loss of 31 cents. Between one and three months ago, the average estimate moved up. It has risen from a loss of 4 cents during the last month.

Past Earnings Performance: The company topped forecasts last quarter after being in line with estimates the quarter prior. In the second quarter, it reported a loss of 82 cents per share versus a mean estimate of 93 cents. Two quarters ago, it reported net loss of $1.05 per share.

Investing Insights: Amazon.com has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 1342.9% in revenue from the year-earlier quarter to $343.4 million.

Analyst Ratings: 11 out of 20 analysts surveyed (55%) have a buy rating on Vertex Pharmaceuticals.. This is below the mean analyst rating of 10 competitors, which average 66.1% buy ratings.

Revenue rose more than threefold to $114.4 million from $31.6 million.

Key Stats:

Revenue has gone up for three straight quarters. It rose more than threefold in the first quarter from the year earlier and 93.3% in the fourth quarter of the last fiscal year.

Competitors to Watch: Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), GlaxoSmithKline plc (NYSE:GSK), InterMune, Inc. (NASDAQ:ITMN), Gilead Sciences, Inc. (NASDAQ:GILD), Pharmasset, Inc. (NASDAQ:VRUS), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Bristol Myers Squibb Co. (NYSE:BMY), Abbott Laboratories (NYSE:ABT), and Human Genome Sciences (NASDAQ:HGSI).

Stock Price Performance: During September 23, 2011 to October 21, 2011, the stock price had dropped $8.99 (-17.7%) from $50.73 to $41.74. The stock price saw one of its best stretches over the last year between June 17, 2011 and June 29, 2011 when shares rose for nine-straight days, rising 16.1% (+$7.26) over that span. It saw one of its worst periods between September 23, 2011 and October 3, 2011 when shares fell for seven-straight days, falling 20.2% (-$10.24) over that span. Shares are up $6.71 (+19.2%) year to date.

(Source: Xignite Financials)

Investing Insights: Amazon.com has a Stock Chart Technical Analysts Dream About.